We provide specialized contract research services for both preclinical and clinical development within allergy, immunology and hypersensitivity. We design and execute tailored studies using our validated BHRA assays (a-BHRA and s-BHRA) and our human ex vivo skin model, with histamine release as a key readout.
Our services support prediction and characterization of immune and adverse immune responses (including pseudoallergic effects) to new therapeutics, from early preclinical assessment and pharmacokinetic profiling through to clinical studies in humans. We are also able to operate in compliance with GCLP requirements.
Contact one of our scientists at info@reflab.dk to learn more or to submit an inquiry.
Preclinical services
RefLab supports preclinical development with specialized in vitro and ex vivo models designed to predict first-in-human immune and adverse immune responses, including pseudoallergic reactions. Our assays are tailored to new biologics, small molecules and excipients, helping you de-risk clinical entry and optimize study design.
Clinical testing
RefLab offers contract analysis of human clinical samples to evaluate immune and hypersensitivity responses in the context of clinical studies. We work with commercial and academic partners who collect the samples; RefLab does not recruit or treat study participants but acts as a specialized central lab for histamine release testing.